We observed that expression of the IKKβ protein was significantly higher in CRC patient samples with both elevated WNT activity plus oncogenic KRAS when compared to those with only elevated WNT activity or KRAS mutations (Fig. 7A–D, quantified in 7I). This evidence concerns the gene KRAS and colorectal carcinoma.